• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

    2/26/25 4:03:00 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KURA alert in real time by email

    – KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint –

    – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial –

    – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 –

    – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 –

    – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting –

    – Management to host webcast and conference call today at 4:30 p.m. ET –

    SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2024 financial results and provided a corporate update.

    "We are very pleased the KOMET-001 registrational trial achieved its primary endpoint. We look forward to sharing topline data at an upcoming medical conference and expect to submit a New Drug Application (NDA) in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML) next quarter," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "In parallel, we are advancing ziftomenib into registrational studies in the frontline (1L) setting. Approximately half of patients with newly diagnosed NPM1-mutated (NPM1-m) AML and 80% of patients with KMT2A-rearranged (KMT2A-r) AML will die from the disease within five years.   Given this unmet need, we are pleased to have reached alignment with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) on key aspects of our Phase 3 trials, including the use of minimum residual disease (MRD)-negative complete response (CR) as a primary endpoint for potential accelerated approval in the U.S., with topline results anticipated in 2028. Our KOMET-017 trial is breaking new ground, and we and our partners at Kyowa Kirin are working as rapidly as possible to bring ziftomenib to AML patients worldwide."

    Recent Highlights

    • Positive topline results from registration-directed trial of ziftomenib in R/R NPM1-m AML – Kura and Kyowa Kirin announced positive topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib in patients with R/R NPM1-m AML. The KOMET-001 trial achieved its primary endpoint, consistent with the targeted 20-30% CR/CR with partial hematological recovery (CRh) rate, and data have been submitted for presentation at ASCO. The benefit-risk profile for ziftomenib is highly encouraging, and safety and tolerability were consistent with previous reports. Facilitated by the Breakthrough Therapy Designation status of ziftomenib in R/R NPM1-m AML, the Company completed its pre-NDA meeting with FDA and anticipates submitting an NDA in the second quarter of 2025.



    • Positive feedback from FDA for 1L combination trial designs – Earlier this month, Kura and Kyowa Kirin announced alignment with FDA on the KOMET-017 global trial protocol evaluating ziftomenib in combination with both intensive and non-intensive combination regimens in patients with newly diagnosed NPM1-m and/or KMT2A-r AML. This includes alignment on potential pathways for accelerated approval in the U.S. in both the KOMET-017-IC (intensive chemotherapy) and KOMET-017-NIC (non-intensive chemotherapy) trials by allowing the trials to use MRD-negative CR and CR, as primary endpoints, respectively. The companies also gained alignment with the EMA on the KOMET-017 protocol, and expect to initiate the KOMET-017 Phase 3 trials in the second half of 2025.



    • Positive clinical data for Phase 1 trial of ziftomenib in combination with standards of care – In December 2024, Kura Oncology and Kyowa Kirin announced encouraging clinical data from KOMET-007, a Phase 1 trial of ziftomenib in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine in patients with NPM1-m and KMT2A-r AML. Among response-evaluable patients enrolled in the 7+3 combination cohort for patients with 1L NPM1-m or KMT2A-r adverse risk AML, 91% achieved a CR (100% for NPM1-m, 83% for KMT2A-r patients). Ziftomenib was generally well tolerated in combination at all dose levels evaluated across all cohorts in the Phase 1a dose-escalation portion of the trial. The positive results from KOMET-007 reported at ASH reinforce the companies' commitment to evaluating ziftomenib across the continuum of 1L AML treatment options.



    • Global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib in acute leukemias – In November 2024, Kura Oncology and Kyowa Kirin announced they entered into a global strategic collaboration to develop and commercialize ziftomenib (Kyowa Agreement), funding the expansive AML development program through U.S. commercialization in 1L combinations. Under the partnership, Kura retains leadership and key strategic rights to ziftomenib in the U.S. and preserves strategic flexibility, while enabling development and commercialization of ziftomenib across the continuum of care in acute leukemias, including both fit and unfit 1L indications, post-transplant maintenance setting and combinations with targeted therapies.



    • Preclinical data supporting opportunity for ziftomenib in treatment of gastrointestinal stromal tumors (GIST) – In October 2024, Kura reported preclinical data presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, supporting the potential for ziftomenib in combination with KIT inhibitors for GIST patients. The combination of ziftomenib and imatinib demonstrated robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST patient-derived xenograft models. Sixty percent of patients develop resistance to imatinib within two years and ziftomenib has the potential to delay the onset of resistance to, or overcome resistance in patients pre-treated with, imatinib. In August 2024, Kura announced clearance by the FDA of an IND application and the Company remains on track to initiate the KOMET-015 trial evaluating ziftomenib plus imatinib in patients with advanced GIST, in the first half of 2025.



    • Clinical and preclinical data support combinations of farnesyl transferase inhibitors with targeted therapies – Despite multiple advances, innate and adaptive resistance remain a challenge for many classes of targeted therapies in cancer. A growing body of clinical and preclinical data demonstrates the potential of farnesyl transferase inhibitors as companion therapeutic agents to augment the antitumor activities of various targeted therapies and overcome resistance in combination. Enrollment in the FIT-001 trial evaluating our next-generation farnesyl transferase inhibitor KO-2806 continues to progress and the dose-escalation portion of the KURRENT-HN trial with tipifarnib is now complete. Kura expects to present the first clinical data for KO-2806 as a monotherapy and in combination, as well as clinical data from the KURRENT-HN trial, in the second half of 2025.

    Financial Results

    • Collaboration revenue from our Kyowa Kirin partnership for the fourth quarter and full year 2024 was $53.9 million, compared to no revenue in 2023.



    • Research and development (R&D) expenses for the fourth quarter of 2024 were $52.3 million, compared to $32.5 million for the fourth quarter of 2023. R&D expenses for the full year 2024 were $170.0 million, compared to $115.2 million for the prior year.



    • General and administrative (G&A) expenses for the fourth quarter of 2024 were $24.1 million, compared to $14.2 million for the fourth quarter of 2023. G&A expenses for the full year 2024 were $77.1 million, compared to $50.6 million for the prior year.



    • Net loss for the fourth quarter of 2024 was $19.2 million, compared to a net loss of $42.8 million for the fourth quarter of 2023. Net loss for the full year 2024 was $174.0 million, compared to a net loss of $152.6 million for the prior year.



    • Net loss for the fourth quarter and full year 2024 included non-cash, share-based compensation expense of $8.6 million and $33.9 million, respectively. This compares to $7.2 million and $28.1 million for the same periods in 2023.



    • As of December 31, 2024, Kura had cash, cash equivalents and short-term investments of $727.4 million, including the upfront payment of $330.0 million from Kyowa Kirin, compared to $424.0 million as of December 31, 2023.



    • Based on our current plans, we believe our cash, cash equivalents and short-term investments as of December 31, 2024 will be sufficient to enable us to fund our current operating expenses into 2027, and combined with anticipated collaboration funding under the Kyowa Agreement, should support our ziftomenib AML program through commercialization in the 1L combination setting.

    Forecasted Milestones

    • Submit an NDA for ziftomenib in R/R NPM1-m AML in the second quarter of 2025.



    • Present topline data from KOMET-001 Phase 2 registration-directed trial in R/R NPM1-m AML in the second quarter of 2025.



    • Present preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib with intensive chemotherapy (7+3) at a medical meeting in the second quarter of 2025.



    • Initiate the KOMET-015 trial evaluating ziftomenib and imatinib in patients with advanced GIST in the first half of 2025.



    • Initiate two independent Phase 3 registration-enabling trials in 1L intensive (KOMET-017-IC) and non-intensive (KOMET-017-NIC) AML in the second half of 2025.



    • Present preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib with venetoclax and azacitidine at a medical meeting in the second half of 2025.



    • Nominate a development candidate for next-generation menin inhibitor program in diabetes in mid-2025.



    • Initiate one or more expansion cohorts of KO-2806 and cabozantinib in patients with advanced renal cell carcinoma in the first half of 2025.



    • Present data from the Phase 1 monotherapy dose escalation of KO-2806 in patients with RAS mutations in the second half of 2025.



    • Present data from the Phase 1 trial evaluating KO-2806 and cabozantinib in patients with renal cell carcinoma in the second half of 2025.



    • Present data from the dose escalation portion of KURRENT-HN trial evaluating tipifarnib and alpelisib in PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC) in the second half of 2025.

    Conference Call and Webcast

    Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT today, February 26, 2025, to discuss the financial results for the fourth quarter and full year 2024 and to provide a corporate update. The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ4. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.

    About Kura Oncology

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the FDA for the treatment of R/R NPM1-m AML. In November 2024, Kura Oncology entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-m AML has been completed, and the companies anticipate submission of an NDA to the FDA in the second quarter of 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-m and KMT2A-r AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent HNSCC. For additional information, please visit Kura's website at www.kuraoncology.com and follow us on X and LinkedIn.

    Forward-Looking Statements

    This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Kura's product candidates, ziftomenib, tipifarnib and KO-2806; plans, trial designs and expected timing of clinical trials; the expected timing and presentation of results and data from clinical trials; the anticipated timing of submission of an NDA for ziftomenib; the potential for U.S. accelerated approval and full approval of product candidates; and the success and impact of interactions with the FDA; the potential for menin inhibitors to shift the treatment paradigm for GIST; the strength of Kura's balance sheet and the sufficiency of cash, cash equivalents and short-term investments to fund its current operating plan to 2027, and combined with anticipated collaboration funding under the Kyowa Agreement, to support Kura's ziftomenib AML program through commercialization in the 1L combination setting. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    KURA ONCOLOGY, INC. 
    Statements of Operations Data 
    (unaudited) 
    (in thousands, except per share data) 
                
     Three Months Ended  Year Ended 
     December 31,  December 31, 
     2024  2023  2024  2023 
    Collaboration revenue$53,883  $—  $53,883  $— 
    Operating expenses           
    Research and development 52,267   32,533   169,967   115,235 
    General and administrative 24,071   14,229   77,111   50,569 
    Total operating expenses 76,338   46,762   247,078   165,804 
    Other income, net 5,256   3,976   21,230   13,173 
    Income tax expense (2,018)  —   (2,018)  — 
    Net loss$(19,217) $(42,786) $(173,983) $(152,631)
    Net loss per share, basic and diluted$(0.22) $(0.55) $(2.02) $(2.08)
    Weighted average number of shares used in computing net loss per share, basic and diluted 87,136   77,337   86,161   73,229 
                
      





          
    KURA ONCOLOGY, INC.

    Balance Sheet Data

    (unaudited)

    (in thousands)

          
     December 31,  December 31, 
     2024  2023 
    Cash, cash equivalents and short-term investments$727,395  $423,957 
    Working capital666,117  397,218 
    Total assets760,159  448,935 
    Long-term liabilities267,807  16,399 
    Accumulated deficit(895,422) (721,439)
    Stockholders' equity413,640  397,273 
          

    Investors:

    Patti Bank

    Managing Director

    (415) 513-1284

    [email protected]

    Media:

    Alexandra Weingarten

    Associate Director, Corporate Communications

    (858) 500-8822

    [email protected]



    Primary Logo

    Get the next $KURA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KURA

    DatePrice TargetRatingAnalyst
    2/6/2025Buy → Neutral
    BTIG Research
    10/24/2024$27.00Buy
    UBS
    10/14/2024$26.00 → $19.00Buy → Hold
    Stifel
    12/22/2023$26.00Buy
    Mizuho
    8/11/2023$31.00Buy
    BofA Securities
    7/27/2023$10.50Sector Perform
    Scotiabank
    5/17/2023$31.00Buy
    BTIG Research
    1/31/2023$25.00Buy
    Stifel
    More analyst ratings

    $KURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kura Oncology downgraded by BTIG Research

      BTIG Research downgraded Kura Oncology from Buy to Neutral

      2/6/25 7:53:07 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Kura Oncology with a new price target

      UBS initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $27.00

      10/24/24 6:23:30 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology downgraded by Stifel with a new price target

      Stifel downgraded Kura Oncology from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      10/14/24 7:36:13 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Kura Oncology Inc.

      SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

      12/5/24 6:55:37 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      11/14/24 4:31:29 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      11/14/24 4:32:22 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Leadership Updates

    Live Leadership Updates

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

      SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. "On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "His extensive experience in R&D and regulatory aff

      9/17/24 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Appoints Brian Powl as Chief Commercial Officer

      SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Brian Powl as Chief Commercial Officer. Mr. Powl joins Kura with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing and executing patient-focused strategies across sales, marketing and market access for global biotech and pharmaceutical products. "Brian is an accomplished leader with a strong track record in building successful commercial organizations and driving global commercial

      8/14/23 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Kura Oncology Inc.

      10-Q - Kura Oncology, Inc. (0001422143) (Filer)

      5/1/25 4:15:19 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Kura Oncology, Inc. (0001422143) (Filer)

      5/1/25 4:10:11 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Kura Oncology Inc.

      DEF 14A - Kura Oncology, Inc. (0001422143) (Filer)

      4/11/25 4:50:53 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hasnain Faheem exercised 22,682 shares at a strike of $6.32 and sold $181,456 worth of shares (22,682 units at $8.00) (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      3/24/25 4:33:39 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Finance & Accounting Doyle Thomas James sold $38,958 worth of shares (4,949 units at $7.87), decreasing direct ownership by 5% to 88,193 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:54:15 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Leoni Mollie sold $39,068 worth of shares (4,963 units at $7.87), decreasing direct ownership by 5% to 88,253 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:39:01 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kura Oncology to Participate in Bank of America Securities Healthcare Conference

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2025 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event. About Kura Oncology Kura Oncology is a clinical-stage biopharm

      5/6/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 433,950 shares of common stock to sixteen (16) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listi

      5/2/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports First Quarter 2025 Financial Results

      – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

      5/1/25 4:05:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KURA
    Financials

    Live finance-specific insights

    See more
    • Kura Oncology Reports First Quarter 2025 Financial Results

      – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

      5/1/25 4:05:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology to Report First Quarter 2025 Financial Results

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and

      4/24/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

      – KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 – – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference

      2/26/25 4:03:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care